When anamorelin was combined with anti-GDF-15 antibody, body weight was elevated compared with the HT-1080 tumour-bearing vehicle group (p < 0.0001) but did not reach statistical significance over anti-GDF-15 antibody alone. Here, GDF15 is linked to neoplasm.